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PANcreatic-DERived factor (PANDER, FAM3B) is a member of the FAM3 family of cytokine molecules
that were initially described in 2002. PANDER expression is primarily localized to the endocrine pan-
creas and is secreted from both pancreatic a and b-cells. Initial characterization of PANDER revealed
a potential role in pancreatic islet apoptosis. However, recent animal models have indicated PAN-
DER functions as a hormone by regulating glucose levels via interaction with both the liver and
the endocrine pancreas. An understanding of the function of PANDER can further the insight into
the mechanisms of glucose regulation and potentially provide additional therapeutic targets for
the treatment of diabetes. This review details the supporting data demonstrating PANDER has a bio-
logical function in glycemic regulation.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction to PANDER: a novel endocrine hormone
PANcreatic-DERived factor (PANDER, FAM3B) was originally
described in 2002 as a result of a search for novel cytokines.
PANDER was primarily localized to the endocrine pancreas and
identiﬁed in both a and b-cells. Initial characterization evaluating
the impact of PANDER on islets revealed induction of apoptosis via
intracellular viral delivery or exogenous recombinant protein appli-
cation. Inductionof islet apoptosis via PANDER is regulated via a cas-
pase-3-dependent mechanism. Additional microarray analysis
indicatedPANDER induced activationof various cell deathpathways
via both caspase-3 and cyclin-dependent kinase inhibitor 1A (p21).
These initial results presented a case for PANDER as a potential acti-
vator or cofactor in the induction of islet apoptosis with regard to
type 1 diabetes. However, recent evidence has begun tomount indi-
cating another biological role for PANDER in the regulation of glyce-
mic levels via interaction with both the liver and the pancreas.
Furthermore, additional studies have demonstrated that PANDER
is signiﬁcantly regulated by both glucose and insulin and further
supports a biological role in glycemic regulation. The initial murky
picture of PANDER has become clearer with the recent creation
and characterization of PANDER animal models including both the
knockout and acute overexpression model. These recent ﬁndingschemical Societies. Published by E
Florida, Department of Cell
13, 4202 E. Fowler Avenue,
dt).havewarranted a comprehensive review of the studies surrounding
PANDER and now signiﬁcantly demonstrate that PANDER repre-
sents a novel hormone with pleiotropic effects on multiple tissues
impacting euglycemia.
2. Identiﬁcation of PANDER
PANDER is one of four members of the family with sequence
similarity 3 (FAM3) of predicted cytokine-like proteins, discovered
through a screen for new cytokines based on the characteristic sec-
ondary structure of a four-helix bundle with up-up-down-down
topology that is stabilized by disulﬁde bonds formed between con-
served cysteines [1]. Whereas primary sequence homology is very
low among cytokines, this secondary structure is highly conserved
[2] and present in many cytokines, including interleukin (IL)-2, -3,
-4, -5, -6, -7, -9, -10, and -13, granulocyte-macrophage colony
stimulating factor (GM-CSF) and growth hormone (GH).
To search for novel families that ﬁt these parameters, the algo-
rithm Ostensible Recognition of Folds (ORF), which predicts the
likelihood that an amino acid in a primary sequence will be in an
alpha helix (a), a beta sheet (b) or a coil (c), was employed [3].
Using probes derived from short chain cytokines such as IL-2, -4
and GM-CSF, the ﬁrst member of the family with sequence similar-
ity 3 member A (FAM3A), was discovered and later conﬁrmed to
have the four-helix bundle structure with four conserved cysteines.
Subsequently, three putative genes were identiﬁed that had signif-
icant homology to FAM3A but not to any other genes. These were
later named FAM3B, FAM3C and FAM3D and comprise the otherlsevier B.V. All rights reserved.
Fig. 1. Secretagogues inducing PANDER expression or secretion. Various factors
have been demonstrated to regulate PANDER. These include insulin, arginine,
glucose, IFNc, TNFa, IL-1b and lipids. Insulin and arginine have increased PANDER
expression and secretion from the a-TC1-6 glucagonoma cell line. Glucose has been
signiﬁcantly demonstrated to increase PANDER expression and secretion from both
isolated pancreatic islets and various pancreatic b-cell lines. IFNc alone or in
combination with TNFa and IL-1b induce PANDER mRNA expression in both
primary islets and pancreatic b-cell lines. A single study has indicated that PANDER
mRNA and protein levels are increased in the livers of high-fat diet-fed mice and
insulin-resistant db/db mice. Concordantly, aged and fat mice have increased levels
of serum PANDER as compared to lean control mice. However, given the fact that
PANDER is expressed to some degree in other tissues (i.e., small intestine, prostate,
and potentially liver) there is uncertainty as to the source of increased PANDER
secretion in these high-fat models. Nonetheless, there is a preponderance of
evidence that indicates that lipids are inducing an increase in PANDER expression
potentially from multiple tissues.
2138 C.G. Wilson et al. / FEBS Letters 585 (2011) 2137–2143members of the FAM3 family. All members have 224–235 amino
acids, including four conserved cysteines and a predicted signal
sequence. Although amino acid sequence homology is only 31.6–
53.3% within the family, the members have no signiﬁcant similar-
ity with any other known cytokines.
FAM3B was later renamed PANcreatic-DERived factor (PANDER)
[4] due its robust expression in the endocrine pancreas. Human
FAM3B shares 78% primary sequence homology with its murine
homolog and also contains 235 amino acids with four conserved
cysteine’s and secretion signal peptide.
3. Tissue-speciﬁc expression within the endocrine pancreas
Characterization of PANDER’s tissue distribution by Northern
blot analysis demonstrated both human and murine PANDER were
very highly expressed in the pancreas and to a minimal extent in
the small intestine followed by the least expression in the prostate
[1]. A recent study detected PANDER mRNA in a broad range of
tissues including muscle and liver [5], but this has yet to be con-
ﬁrmed by other groups. Quantitative real time PCR (q-PCR) analy-
sis of various murine tissues further conﬁrmed the pancreatic
expression of PANDER [6]. Similarly, murine PANDER mRNA levels
have been quantiﬁed in various pancreas-derived cell lines. Using
muscle-derived C2C12 cells as a negative control, the a-cell
derived cell line, a-TC3 had the highest level of PANDER mRNA
compared to the b-cell derived b-TC3 cells [7,8]. Similarly, in
ﬂuorescence-activated cell sorted murine pancreatic islet cells,
PANDER mRNA expression was highest in the glucagon positive,
a-cell enriched population, at levels six-fold more than in the insu-
lin positive, b-cell enriched population. PANDER mRNA was also
detected in a-TC1–9 and a-TC1–6 a-cell lines and the MIN-6 b-cell
line [9,10]. However, despite relatively high PANDER expression in
these cell lines, murine islets have mRNA levels at least 100-fold
greater than in pancreatic-derived cell lines [7].
Immunohistochemical (IHC) staining for murine PANDER pro-
tein revealed speciﬁc localization to the islet of Langerhans of the
endocrine pancreas with no expression in the exocrine pancreas.
This was conﬁrmed in both human and rat islets, in which immu-
no-ﬂuorescence staining for PANDER overlapped signiﬁcantly with
both insulin positive b-cells and glucagon positive a-cells. PANDER
protein was also detected in b-TC3 and a-TC3 cell lines [4,8].
4. Localization within pancreatic a and b-cells
Analysis of PANDER’s sub-cellular localization within b-cells by
immunogold electron microscopy and confocal microscopy
indicated that PANDER was co-localized with insulin to secretory
vesicles [8]. In aTC1–6 cells, PANDER was detected in the gluca-
gon-negative granular cytosolic compartment including cytoplas-
mic granules, neuroendocrine vesicles, endoplasmic reticulum
(ER), and the cis-Golgi [10].
5. Transcriptionally regulated expression
The murine PANDER gene consists of eight exons spanning an
approximate 32 kb region located on chromosome 16B-C4 [1].
Human chromosomal location for PANDER is syntenic to human
chromosome 21q22. For murine PANDER, a single transcriptional
start site located 520 bp upstream of the translational start codon
has been identiﬁed [7]. The murine promoter contains several tran-
scriptional binding sites for elements that are known to confer
both pancreatic-islet speciﬁc and glucose-responsive expression
similar to that of insulin [7]. In the region between 335 and
+523 relative to the transcriptional start site there are binding sites
for A and E box elements, hepatic nuclear factors (HNF) 1 and 4a,and signal transducer and activation of transcription (STAT) 3, 5,
and 6. These A and E box elements were hypothesized to confer tis-
sue speciﬁc PANDER expression by allowing the interaction of
transcription factors such as Pancreatic/Duodenal Homeobox do-
main-1 (PDX-1) and b-cell E box Transactivator 2 (BETA2/NeuroD),
respectively, which are important for pancreas development and
conferring islet speciﬁc expression of many islet genes. In ﬁbro-
blast cells, co-transfection of a construct that expresses luciferase
under control of the PANDER promoter, with plasmids directing
over expression of islet-speciﬁc transcription factors (TFs) MafA,
BETA2/NeuroD and PDX-1 revealed that although all three TFs
individually increased luciferase activity above control levels,
PDX-1 had the greatest impact. Furthermore, PDX-1 bound to three
A box sites within the PANDER promoter, and simultaneous abla-
tion of two of these sites signiﬁcantly abrogated PANDER promoter
activity [11].
Besides conferring tissue speciﬁc expression, these binding mo-
tifs are also known to promote glucose responsive expression. Glu-
cose robustly induced PANDER promoter activity in both b-TC3
cells and mouse islets in a dose-dependent manner, and PDX-1
may be involved in this glucose responsive regulation [11]. Wang
et al. conﬁrmed this glucose responsive regulation in MIN6 cells,
in which glucose signiﬁcantly increased PANDER transcription via
a cAMP regulator element binding protein (CREB)-dependent
mechanism [9]. Glucose-stimulated transcription occurred via
either Ca2+/PKA/ERK1/2 or Ca2+/PKC/ pathway, and blockage of
these pathways signiﬁcantly reduced PANDER promoter activity
and gene expression. No glucose responsive promoter activity
was observed in a-TC3 cells despite high levels of PANDER mRNA
[7]. In addition to glucose, a combination of the pro-inﬂammatory
cytokines, interleukin-1b (IL-1b), tumor necrosis factor (TNFa), and
interferon-c (IFNc) also robustly increased PANDER mRNA in b-
TC3 cells and mouse islets [8] (Fig. 1). IFNc alone produced a
three-fold increase that was both time- and dose-dependent.
6. Glucose and insulin-regulated secretion
Like the other members of the FAM3 family, PANDER has a
hydrophobic leader sequence on its N-terminus suggesting that it
C.G. Wilson et al. / FEBS Letters 585 (2011) 2137–2143 2139will be targeted to the ER and processed within cells for secretion.
As previously mentioned, PANDER is localized within the ER and
Golgi of aTC1–6 cells and in secretory vesicles in b cells. In CHO
cells overexpressing human PANDER, PANDER was detected in
the culture media and determined to be a monomer by analytical
ultracentrifugation and non-reducing gel electrophoresis. Two
N-termini were identiﬁed at either Glutamate 30 or Serine 46
[1]. Similarly, two N-termini were identiﬁed for murine PANDER
expressed in Pichia pastoris, Serine 46 and Alanine 55, a possible
variant product from Pichia production. Cleavage at these two sites
resulted in proteins of molecular weights 21 and 20 kDa, respec-
tively. In transfected b-TC3 cells or primary hepatocytes infected
with PANDER adenovirus, 26 and 23 kDa products were detected
in lysate and media, respectively, presumably the full length and
Glutamate 30-cleaved PANDER, potentially carrying post-transla-
tional modiﬁcations due to expression in mammalian cells.
The localization of PANDER to insulin granules in b-cells sug-
gested that PANDER might be co-secreted with insulin in response
to glucose. In b cell lines, PANDER and insulin secretions were in-
creased with glucose incubation in a dose- and time-dependent
manner [9,12] (Fig. 1). Potassium chloride, a potent insulin secreta-
gogue, also caused a robust increase in PANDER secretion. Chronic
glucose stimulation also signiﬁcantly increased PANDER secretion
from mouse islets overexpressing PANDER in b-cells. Therefore, it
was concluded that PANDER secretion from b-cells is regulated in
a manner similar to insulin secretion.
In a-cells, neither increasing nor decreasing glucose concentra-
tions had any effect on PANDER secretion or content. This sug-
gested that in the whole islets, the dominant source of secreted
PANDER in response to glucose is the b-cell. However in aTC1-6
cells, arginine, a potent stimulator of glucagon secretion, increased
PANDER secretion at concentrationsP10 mM [10] (Fig. 1). Surpris-
ingly, low insulin concentrations (17 or 50 nM) also stimulated
PANDER release from a-cells more robustly than arginine. Studies
performed by Carnegie et al. utilizing a C-terminal PANDER-FLAG
fusion protein revealed PANDER localization to a glucagon-nega-
tive granular cytoplasmic compartment in a-TC1–6 cells. PANDER,
if it is secreted in tandem with glucagon, is not likely to contribute
to PANDER levels in the blood during stimulated insulin secretion
when paracrine regulated glucagon release may be inhibited by
insulin. Nonetheless, the nutrient and hormonal regulation of PAN-
DER is consistent with a potential glucoregulatory function (Fig. 1).Table 1
Phenotypic comparison of PANDER adenoviral and knockout mice.
Ad-PANDER PANDER KO
Fasting blood glucose Elevated No difference in mice
on normal diet
Lower in mice on HFD
Fasting serum metabolites " Insulin
" Corticosterone
" Insulin
" Leptin
Glucose tolerance Impaired due to
fasting
hyperglycemia
Impaired due to
impaired b-cell
function
Hepatic glucose production
by HE-clamp
Not evaluated Decreased
Glucose production from
primary hepatocytes
Increased Not evaluated
Gluconeogenic gene
expression (PEPCK and
G6Pase)
Elevated Decreased
b-Cell cell function Normal Decreased7. Biological impact of PANDER in vitro and in vivo
7.1. To b or not to b?: induction of b-cell apoptosis and impact on
b-cell function
Initial assessment of a potential autocrine effect of PANDER
demonstrated that islets and b-TC3 cells treated with recombinant
PANDER (typically in the nanomolar range) or PANDER adenovirus
(which expresses full length PANDER) had high levels of apoptotic
and necrotic cell death compared to untreated cells [4,13]. The in-
crease in apoptosis was not accompanied by changes in the protein
levels of apoptotic mediators such as Akt, STAT1, NF-jB, and Fas
known to be important for cytokine-induced autoimmune b-cell
death [13]. However, PANDER-induced apoptosis was mediated
by caspase-3 cleavage, without any effect on intracellular Ca2+ or
nitric oxide (NO) production suggesting the involvement of ‘‘non-
canonical’’ pathways.
In a microarray study of PANDER-treated islets, 20% of the genes
differentially expressed after 48 h were associated with cell death
compared to 47% after 72 h of treatment [14]. Genes with the high-
est fold changes included cyclin-dependent kinase inhibitor 1A
(CDKN1A/p21), insulin like growth factor binding protein (IGFBP4)and lipocalin 2 (LCN2). The anti-apoptotic gene CDKN1A/p21,
downregulated 3.4-fold with PANDER treatment, appeared to be
central to several apoptotic networks which included caspase-3
and 7. Cleaved caspase-3 protein levels were also increased in
PANDER-treated b-TC3 cells with a subsequent decrease in
CDKN1A, indicating that CDKN1A/caspase-3 network appears to
be important for PANDER-induced b-cell death.
In addition to b-cell apoptosis, recombinant PANDER treatment
decreased basal insulin secretion from b-TC3 cells but had no effect
on glucose stimulated secretion or b-cell glucose metabolism [1].
Overexpression of PANDER in isolated murine islets via adenoviral
delivery or recombinant protein application had no impact on glu-
cose-stimulated insulin secretion (GSIS), yet insulin secretion was
impaired in the presence of glucose with various insulin secreta-
gogues such as carbachol (muscarinic agonist) or potassium chlo-
ride [13]. From these experiments, it was concluded that PANDER
appears to impact the amplifying not initiating signals of GSIS sug-
gesting potential defects in calcium signaling. Unfortunately, cal-
cium signaling was not evaluated within islets overexpressing
PANDER.
PANDER/ (PANKO) mice did not display any abnormalities in
pancreatic islet architecture, or expression of various genes in-
volved in GSIS [6]. However, with regard to function, insulin secre-
tion in response to arginine injection was blunted and pancreatic
islets isolated from these mice showed diminished GSIS and abnor-
mal Ca2+ response to glucose. The intracellular calcium response in
PANKO islets differed from wild-type with the following observa-
tions: hyper-response of Ca2+ at low glucose (3 mM) conditions;
lack of transient Ca2+ decrease immediately following high glucose
(16 mM) stimulation attributed to uptake by the sarco-endoplas-
mic reticulum Ca2+ ATPase (SERCA) pumps; impaired amplitude
of Ca2+ at high glucose condition, and blunted KCl response. The
observed abnormal Ca2+ handling identiﬁed in the pancreatic islets
may provide a causative mechanism for the observed impaired
GSIS in vitro and glucose intolerance observed in vivo (Table 1).
However, in mice overexpressing PANDER by adenoviral gene
delivery with targeted hepatic PANDER overexpression, increasing
circulating PANDER levels did not affect fractional insulin secretion
or islet insulin content [15] (Table 1). These ﬁndings are discordant
from the results in both the PANKO mice and isolated pancreatic
islets overexpressing PANDER and this may be attributed to several
reasons including different experimental models (KO versus liver-
speciﬁc overexpression) or site and amount of PANDER overex-
pression (liver versus pancreatic islets). Overall, the compilation
of results indicate that PANDER is acting within the pancreatic is-
lets to promote b-cell function and suggests a role for intracellular
PANDER in the regulation or facilitation of insulin secretion (Fig. 2).
Glucose
Pancreatic
Islets
cAMP and CREB
Gluconeogenesis
HGP
Liver
PANDER
Promote -cell 
function
Insulin
Pancreatic
Islets
cAMP and CREB
Gluconeogenesis
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Liver
PANDERInsulin
Fasting condition 
in Aged/Obese 
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in mice
Lipids
Fig. 2. Mechanism of PANDER action during the fasted and fed state in the regulation of euglycemia. Evidence to date indicates that PANDER is a novel hormone that is
counterregulatory to insulin. In addition, PANDER has been demonstrated to promote pancreatic b-cell function but not stimulate but rather enhance or facilitate insulin
secretion. Multiple secretagogues have been identiﬁed that stimulate PANDER secretion from pancreatic islets including glucose, lipids, and insulin (for a-cells). Therefore,
post-prandial ingestion of these various nutrients and subsequent release of insulin would induce PANDER release. In lean mice, PANDER levels are low during fasting but in
age- or diet-induced obesity, PANDER levels are high in fasted mice possible due to a stimulatory effect of lipids on the b-cells (left panel). In the absence of high insulin levels,
high circulating PANDER levels impact the liver to increase cAMP and pCREB with subsequent upregulation of critical gluconeogenic enzymes of G6Pase and PEPCK gene
expression. This results in an overall increase in HGP and fasting hyperglycemia. With refeeding, glucose stimulates both PANDER and insulin secretion from the b-cells (right
panel). In the presence of high insulin levels and its strong suppressive effect on HGP, the effect of PANDER on the liver is blocked and HGP is shut down. Therefore, PANDER
expression and secretion induced during post-prandial conditions would be to strictly enhance b-cell function and calcium handling within the pancreatic islet itself.
However, distal action in the liver would be serving a function counter-regulating insulin action.
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production
In a screen for extra-pancreatic targets of PANDER, speciﬁc
binding of 125I-PANDER to liver membrane was detected [16] indi-
cating that there might be a hepatic PANDER receptor. In HepG2
cells, a human hepatoma cell line, recombinant PANDER treatment
resulted in an inhibition in insulin signaling as measured by
decreased activation of the insulin receptor-b (IRb), insulin recep-
tor substrate-1 (IRS-1), phosphatidylinositol-30-OH-kinase (PI3K),
and Akt [16]. In primary murine hepatocytes, PANDER treatment
increased cAMP and cAMP-responsive element binding protein
(CREB) signaling [15]. These effects were proposed to have
occurred via interaction with the unidentiﬁed hepatic PANDER
receptor.
The effect of circulating PANDER on the liver appears to be
important for regulating hepatic glucose production (HGP) during
fasting. In mice, PANDER overexpression promotes hyperglycemia,
compensatory hyperinsulinemia, decreased liver triglycerides, and
elevated corticosterone levels only in fasted mice [15] (Table 1),
but does not affect ad libitum fed glucose levels or serum metabo-
lites. Even the glucose intolerance observed in these mice was due
to elevated fasting glucose levels. The increase in fasting glucose
was accompanied by increased transcription of hepatic phospho-
enolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase(G6Pase). In vitro, PANDER-treated hepatocytes demonstrated ele-
vated glucose production and gluconeogenic gene expression.
Mechanistically, the effect on gluconeogenic transcription and glu-
cose output appeared to be due to enhanced cAMP and CREB sig-
naling after stimulation with forskolin or 8-bromocAMP and
dexamethasone, respectively, and not to any impairment in insu-
lin’s ability to suppress HGP.
Concordantly, PANKO mice displayed a decrease in HGP during
a hyperinsulinemic-euglycemic clamp and decreased gluconeo-
genic gene expression in fasting PANKOmice compared to WT con-
trols. Surprisingly, glucose levels were not altered in PANKO mice
compared to controls. The compilation of data from both the ani-
mal models and in vitro data indicate that during fasting, the liver
represents a strong distal target for PANDER action with subse-
quent impact on hepatic gluconeogenesis and overall regulation
of euglycemia (Fig. 2).
In addition to the extracellular actions we have observed, Li et
al. reported that PANDER is found in hepatocytes, with increased
expression in steatotic livers of diabetic (db/db) and high fat diet
(HFD, 60% fat by calories) fed mice. Furthermore, knockdown of
PANDER within the liver attenuated hyperglycemia (and insulin
resistance) in db/db mice. Concordantly, PANDER overexpression
in liver promoted lipogenesis, lipid accumulation, and Forkhead
box 1 (FOXO1) expression. Conversely, overexpression of FOXO1
increased hepatic PANDER levels [5]. No information on PANDER
HyperinsulinemiaHyperglycemia
Hyperlipidemia
Pancreatic
Islets
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was reported.
9. PANDER, lipids and hyperglycemia
Presently, the only physiological condition under which we
have observed chronically elevated circulating PANDER levels is
in fat, aged C57Bl/6 mice [17]. Two striking differences in PANDER
levels were observed in these mice compared to young, lean mice:
(1) PANDER levels were signiﬁcantly higher both during feeding
and fasting and (2) serum levels in fat mice did not decrease with
fasting as is seen in lean mice (levels are two-fold lower with fast-
ing), but remained high. These data suggest that there is a positive
correlation between increased body fat and elevated PANDER lev-
els. Furthermore, while ad libitum fed glucose levels were not sig-
niﬁcantly different between the two groups, after a 24-h fast, fat
mice were hyperglycemic compared to lean mice. Therefore, ele-
vated fasting PANDER levels in these fat mice may be an important
contributor to fasting hyperglycemia due to increased hepatic glu-
cose production. While increased triglyceride storage may promote
hyperglycemia [18–20], it is unlikely that PANDER is just an inno-
cent bystander. For example, in mice overexpressing PANDER in
the b-cell, there was an increased onset of HFD-induced glucose
intolerance compared to WT controls [21].
Conversely, while there were no differences in fasted glucose
levels in the PANKO mice on normal chow diet, after HFD feeding
for 10 weeks, glucose levels following a 24- or 48-h fast were
signiﬁcantly lower in PANKO mice [17,22] and more similar to
their normal diet (ND, 16.7% fat by calories) fed counterparts. This
suggests that loss of PANDER may protect mice on a HFD
from developing gross fasting hyperglycemia and that PANDER
may be an important target for inhibiting HFD-induced fasting
hyperglycemia.
Mechanistically, a positive effect of lipids on PANDER secretion
is not implausible as free fatty acids (FFAs) promote insulin secre-
tion. As PANDER is co-stored and -secreted with insulin, higher
PANDER levels in fat mice may be due to a FFA-induced stimula-
tion of insulin secretory vesicles. A similar effect has been observed
for amylin, a peptide that is also localized to insulin secretory ves-
icles and co-secreted with insulin [23–25]. FFAs increase amylin
mRNA expression and protein [26] and long-term HFD feeding in
mice increases plasma amylin levels [27,28]. Amylin secretion is
also increased in obesity, and insulin resistance and decreased in
patients with T2DM [29]. A similar mechanismmight explain high-
er circulating PANDER levels in fat mice.HGP
Liver PANDER
Fig. 3. PANDER and the potential progression of type 2 diabetes. Type 2 diabetes is
characterized by a progressive loss of glucose tolerance as a result of impaired
insulin sensitivity. Several hallmarks of this disease include increased glycemic and
insulin levels along with potential hyperlipidemia. Concordantly, both glucose and
insulin have been identiﬁed to stimulate PANDER secretion from both pancreatic b
and a-cells, respectively. In addition, PANDER sera levels are increased in aged and
heavier mice. This condition may also stimulate PANDER levels during type 2
diabetes or metabolic syndrome and ultimately result in increased hepatic glucose
production and increased glycemic levels. Therefore, one potential therapeutic
option would be to inhibit PANDER hepatic action and improve glycemic control via
inhibition of hepatic glucose output.10. PANDER as a therapeutic target for diabetes
Type 2 diabetes is characterized by a progressive loss of glucose
tolerance over several years due to three key abnormalities: im-
paired insulin secretion, impaired insulin action in liver, muscle,
adipose, and abnormal splanchnic glucose metabolism [30–32].
Prior to the development of diabetes, many pre-diabetic patients
present with impaired fasting glucose (fasting hyperglycemia)
and/or impaired glucose tolerance (IGT) [33,34], which are both
risk factors for the development of T2DM [35]. Additionally, there
is a strong correlation between the severity of fasting hyperglyce-
mia in T2DM and increased HGP [36,37]. As fasting hyperglycemia
predicts unusually high post-prandial glucose in humans [38], the
development of drugs to treat this condition has strong clinical
relevance.
Data generated from both of our PANDER animal models have
revealed multiple metabolic abnormalities that are shared with
the pathogenesis of type 2 diabetes including increased hepatic
glucose output (Table 1). Therefore, the signiﬁcance of PANDER isthat it represents a potential molecule that may impact diabetes
based on the effect that PANDER has on target tissues involved in
glucose regulation.
It is interesting to note that in fed insulin sensitive mice there,
does not appear to be an effect of PANDER on the liver to promote
HGP. This is likely due to two reasons. (1) Insulin exerts a very
strong suppressive effect on HGP even if PANDER is present and
(2) PANDER enhances stimulated levels HGP but cannot itself di-
rectly increase HGP. Therefore in the fed state the liver does not ap-
pear to be PANDER’s primary target. However, in fasted mice,
signals that act via cAMP and CREB dependent pathways increase
gluconeogenic gene expression and HGP. Furthermore, low insulin
levels during fasting do not inhibit these processes. When PANDER
levels are high under these conditions, such as in aged, fat mice,
then PANDER enhances cAMP and CREB signaling to promote fast-
ing hyperglycemia. In addition, small interfering RNA (siRNA)-
mediated knockdown of hepatic PANDER signiﬁcantly attenuated
steatosis, insulin resistance, and fasting levels in db/db mice [5].
Therefore, PANDER’s effect on the liver is revealed under the path-
ophysiological state of excess fat and insulin resistance.
One potentially attractive target for a novel class of type 2 dia-
betic compounds could be focused on the inhibition of PANDER he-
patic signaling to block HGP and improve hepatic insulin
sensitivity either at the receptor level or intracellularly. Further-
more, reducing circulating PANDER may also be beneﬁcial as high
PANDER levels may indirectly promote fasting hyperglycemia via
corticosterone (the active glucocorticoid in mice) which is signiﬁ-
cantly higher in fasted mice overexpressing PANDER [15]. Like-
wise, many rodent models of T2DM are associated with elevated
glucocorticoids levels [39] but antagonism of hepatic glucocorti-
coid signaling normalizes elevated HGP and improves glycemic
control [40,41].
Furthermore, conditions that perpetuate type 2 diabetes includ-
ing hyperglycemia, and hyperlipidemia would all contribute to
hyperPANDERemia since these conditions have previously been
demonstrated to increase PANDER expression and would
2142 C.G. Wilson et al. / FEBS Letters 585 (2011) 2137–2143subsequently result in induction of increased HGP and glycemic
levels (Fig. 3). Therefore, not only might therapeutic intervention
of PANDER action decrease glycemic levels but also inhibit the fur-
ther progression of type 2 diabetes.
11. Concluding remarks
In conclusion, as the ﬁeld of PANDER research continually
expands it has become more evident that PANDER represents a
novel hormone that serves a biological function in the regulation
of glycemic levels via interaction with both the endocrine pancreas
and liver. PANDER is intimately coupled to insulin with regard to
modiﬁcation of both its action and secretion. Several of the causa-
tive parameters associated with both type 1 (increased cytokine
expression) and type 2 (hyperlipidemia, hyperglycemia, and
hyperinsulinemia) diabetes may increase circulating PANDER
levels and perpetuate hyperglycemia and glucose intolerance. This
may initiate or exacerbate progression of diabetes mellitus (Fig. 3)
and therefore the inhibition of hepatic PANDER action may provide
a therapeutic option to prevent the further deterioration of glyce-
mic control.
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